Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis

Xueqiong Xun, Qinguang Cao, Hong Pan, Saroj Rai, Yeming Zhou, Ruikang Liu, Huiyong HuFrontiers in Oncology 2022 · DOI

TL;DR

This meta-analysis of 11 randomized controlled trials (RCTs) found that adding capecitabine to standard chemotherapy significantly improves disease-free survival (DFS) and overall survival (OS) for early-stage triple-negative breast cancer (TNBC). Notably, lower doses and higher frequencies of capecitabine, particularly in adjuvant settings, showed better survival outcomes with manageable side effects.

What Problem Does This Paper Address?

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by a lack of estrogen receptors (ER), progesterone receptors (PR), and HER2. This makes it unresponsive to hormonal therapies and targeted treatments, leaving chemotherapy as the primary treatment option. Despite standard chemotherapy regimens, TNBC has a high recurrence rate and poor prognosis, necessitating the exploration of new or improved therapeutic strategies. Capecitabine, an oral prodrug of 5-fluorouracil, has shown promise in other cancers, but its efficacy and safety specifically for early-stage TNBC, especially when combined with standard chemotherapy, remained a subject of debate due to heterogeneous results from individual studies. This paper aims to provide a comprehensive meta-analysis to clarify these benefits and risks.

Methods

The researchers conducted a systematic meta-analysis by searching four major databases (Medline, Embase, Web of Science, and Cochrane) for relevant randomized controlled trials (RCTs) published up to March 18, 2022. They included phase III RCTs where the experimental group received capecitabine-based chemotherapy, and the control group received chemotherapy without capecitabine. The primary outcomes assessed were disease-free survival (DFS) and overall survival (OS), using hazard ratios (HRs) and 95% confidence intervals (CIs). Adverse events, specifically grade 3-5 events like neutropenia, diarrhea, fatigue, and hand-foot syndrome, were also analyzed using odds ratios (ORs). Heterogeneity was assessed using Cochrane Q and I² statistics, with random-effects models employed when heterogeneity was significant (p ≤ 0.05 or I² > 50%) and fixed-effects models otherwise. Subgroup analyses were performed based on capecitabine dosage, number of cycles, treatment setting (neo-/adjuvant), menopausal status, lymph node status, and Ki-67 levels. Quality of included studies was assessed using the Cochrane Risk of Bias Assessment Tool (CROBAT).

Datasets

The study did not introduce new datasets. Instead, it synthesized data from 11 existing randomized controlled trials (RCTs) involving a total of 5,175 female patients. These RCTs were identified through systematic database searches.

Key Insights and Ideas

  • Capecitabine as a valuable addition: The meta-analysis strongly supports the role of capecitabine as an adjunct to standard chemotherapy for early-stage TNBC, demonstrating significant improvements in both DFS and OS.
  • Dosage and frequency matter: A key finding is that lower doses (specifically <1000 mg) and higher frequencies of capecitabine administration appear to yield better survival outcomes compared to higher doses. This suggests a potential for optimizing treatment regimens to maximize efficacy while minimizing toxicity.
  • Adjuvant vs. Neoadjuvant: Capecitabine showed a significant benefit when used as adjuvant chemotherapy, but not when used as neoadjuvant chemotherapy in this analysis. This distinction is important for treatment planning.
  • Manageable adverse events: While capecitabine is associated with increased risks of certain adverse events, particularly diarrhea, hand-foot syndrome, and leukopenia, these were generally considered tolerable and manageable, especially with early recognition and supportive measures.
  • Subgroup insights: The analysis revealed that patients with premenopausal status and lower Ki-67 levels (<30%) might benefit more from capecitabine treatment, highlighting potential personalized treatment approaches.

Key Results

  • DFS Improvement: The addition of capecitabine significantly improved DFS with a hazard ratio (HR) of 0.77 (95% CI 0.68–0.86) and low heterogeneity (I² = 7%).
  • OS Improvement: Overall survival (OS) also showed a significant improvement with an HR of 0.73 (95% CI 0.63–0.85) and very low heterogeneity (I² = 0%).
  • Dosage Subgroup: The group receiving ≥1,000 mg capecitabine showed a significant DFS improvement (HR=0.79, 95% CI 0.69–0.91), while the <1,000 mg group also showed improvement (HR=0.69, 95% CI 0.54-0.88), with the lower dose group demonstrating a better survival outcome.
  • Adverse Events: Capecitabine was associated with significantly higher rates of diarrhea (OR=3.10, 95% CI 2.32–4.15), hand-foot syndrome (OR=25.79, 95% CI 15.32–43.42), and leukopenia (OR=2.08, 95% CI 1.13–3.84).

Limitations and Future Work

The authors acknowledge several limitations:

  • Heterogeneity in regimens: The chemotherapy regimens used in the included RCTs varied, combining different anthracyclines, taxanes, and cyclophosphamides, which could contribute to heterogeneity in the results.
  • Subgroup analysis for TNBC: In some studies, TNBC patients were treated as a subgroup, leading to potential missing baseline information and reduced quality of conclusions.
  • Adverse event reporting: The reporting of adverse events varied across studies, and the effect of these events might be biased due to the lack of comprehensive data.

Future research could focus on further optimizing capecitabine dosage and frequency, particularly for specific patient subgroups, and on developing strategies to mitigate its adverse effects, especially hand-foot syndrome. Investigating the underlying mechanisms for the differential efficacy in adjuvant versus neoadjuvant settings would also be valuable.

Summary updated

Abstract

The addition of capecitabine to early-stage TNBC patients receiving standard adjuvant chemotherapy showed significant DFS and OS improvement with tolerable adverse events. The lower dosage and higher frequency of capecitabine combined with adjuvant chemotherapy demonstrated a better survival outcome.
BibTeX
@inproceedings{xun2022efficacy,
  author = {Xueqiong Xun and Qinguang Cao and Hong Pan and Saroj Rai and Yeming Zhou and Ruikang Liu and Huiyong Hu},
  title = {{Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.899423},
}
Figure